168 related articles for article (PubMed ID: 29755112)
1. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
Lohneis P; Sinn M; Klein F; Bischoff S; Striefler JK; Wislocka L; Sinn BV; Pelzer U; Oettle H; Riess H; Denkert C; Bläker H; Jühling A
Br J Cancer; 2018 May; 118(11):1485-1491. PubMed ID: 29755112
[TBL] [Abstract][Full Text] [Related]
2. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
[TBL] [Abstract][Full Text] [Related]
3. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
[TBL] [Abstract][Full Text] [Related]
4. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.
Petrova E; Zielinski V; Bolm L; Schreiber C; Knief J; Thorns C; Bronsert P; Timme-Bronsert S; Bausch D; Perner S; Keck T; Wellner U
Virchows Arch; 2020 Apr; 476(4):561-568. PubMed ID: 31786688
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma.
Pergolini I; Crippa S; Pagnanelli M; Belfiori G; Pucci A; Partelli S; Rubini C; Castelli P; Zamboni G; Falconi M
BJS Open; 2019 Oct; 3(5):646-655. PubMed ID: 31592095
[TBL] [Abstract][Full Text] [Related]
7. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
8. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
[TBL] [Abstract][Full Text] [Related]
10. Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma.
Lohneis P; Hieggelke L; Gebauer F; Ball M; Bruns C; Büttner R; Löser H; Quaas A
Virchows Arch; 2021 Mar; 478(3):393-400. PubMed ID: 32761393
[TBL] [Abstract][Full Text] [Related]
11. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
O'Connor K; Li-Chang HH; Kalloger SE; Peixoto RD; Webber DL; Owen DA; Driman DK; Kirsch R; Serra S; Scudamore CH; Renouf DJ; Schaeffer DF
Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
[TBL] [Abstract][Full Text] [Related]
12. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM.
Marchegiani G; Andrianello S; Malleo G; De Gregorio L; Scarpa A; Mino-Kenudson M; Maggino L; Ferrone CR; Lillemoe KD; Bassi C; Castillo CF; Salvia R
Ann Surg; 2017 Jul; 266(1):142-148. PubMed ID: 27322188
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
Lohneis P; Sinn M; Bischoff S; Jühling A; Pelzer U; Wislocka L; Bahra M; Sinn BV; Denkert C; Oettle H; Bläker H; Riess H; Jöhrens K; Striefler JK
Eur J Cancer; 2017 Sep; 83():290-301. PubMed ID: 28772128
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
15. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
[TBL] [Abstract][Full Text] [Related]
16. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience.
Koelzer VH; Assarzadegan N; Dawson H; Mitrovic B; Grin A; Messenger DE; Kirsch R; Riddell RH; Lugli A; Zlobec I
J Pathol Clin Res; 2017 Jul; 3(3):171-178. PubMed ID: 28770101
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
19. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Calomme A; Demetter P; Delpero JR; Svrcek M; Cros J; Bardier-Dupas A; Puleo F; Monges G; Hammel P; Louvet C; Paye F; Bachelier P; Le Treut YP; Vaillant JC; Sauvanet A; André T; Salmon I; Devière J; Emile JF; Van Laethem JL
Clin Cancer Res; 2015 Mar; 21(5):1215-24. PubMed ID: 25552484
[TBL] [Abstract][Full Text] [Related]
20. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.
Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Bui JL; Yuan C; Qian ZR; Babic A; Da Silva A; Nowak JA; Khalaf N; Brais LK; Welch MW; Zellers CL; Ng K; Chang DT; Miksad RA; Bullock AJ; Tseng JF; Swanson RS; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Hornick JL; Ogino S; Fuchs CS; Hezel AF; Koong AC; Wolpin BM
Br J Cancer; 2017 Dec; 117(12):1874-1882. PubMed ID: 28982112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
